Compare Kraft Heinz Co (KHC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Repligen Corporation Common Stock — how do they compare? Kraft Heinz Co trades at $23.04 (market cap $26.92B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Kraft Heinz Co is far larger — about 2.4× Repligen Corporation Common Stock's market cap, and Kraft Heinz Co pays a 7.05% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Repligen Corporation Common Stock for 0 Days on average.
| KHC | RGEN | |
|---|---|---|
Market Cap | $26.92B | $11.31B |
Volume | 12,540,089 | 1,216,919 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $194.57 |
52-Week Low | $21.21 | $102.87 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $43.24B | $11.20B |
Dividend Yield | 7.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.43, down 0.09% with bearish technical signals despite recent earnings beats. The company faces fundamental challenges with a net loss of $5.85 billion in 2025 and negative profit margins, though operating cash flow remains strong at $4.46 billion. Recent news highlights ongoing turnaround efforts including new product launches and a $700 million reinvestment strategy to revive brands.
The stock presents a mixed outlook with attractive valuation metrics (P/E 13.04, P/B 0.74) and 6.5% dividend yield, but significant execution risks persist. Analyst consensus leans cautious with 57% hold ratings, while institutional interest remains with recent large purchases. Key risks include continued volume declines, high debt load, and competitive pressures in the consumer goods sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
